European Journal of Biomedical and Pharmaceutical Sciences

USE OF GENOTYPE MTBDR ASSAY FOR MOLECULAR DETECTION OF RIFAMPIN AND ISONIAZID RESISTANCE IN MYCOBACTERIUM TUBERCULOSISCLINICAL STRAINS ISOLATED IN SUDAN

Ahmed Musa Abdallah*, Mohammed Ahmed Mohammed and Najwa Juda Adam

ABSTRACT

Introduction: The most effective first line drug against Mycobacterium tuberculosis are rifampicin and isoniazid, mutations in several gene determinant resistance Mycobacterium tuberculosis to isoniazid and most common gene target is katG and resistance rifampicin due to mutation in rpoB. The aim to assess to mutation in the gene region related to rifampicin and isoniazid. Methodology: A total of 200 smear positive samples were subjected to line probe assay using genotype MTB DR plus assay (HainLifescience Germany). Result: Out of 220 sputum samples, The smear positive were 200(90%) and smear negative were 20(10%), positive smears were subjected to MTBDR plus assay, Valid MTBDR plus assay results were obtained for 156 of 200 (78 %) . Of the 156, 80 (51.3%) tests were found to be resistant and 68(85%) of 80 were resistant to both RIF and INH, 76( 95 %) of 80 were resistant to RIF only, 78(97.5%) of 80 was isoniazid resistant were resistant to INH only. Conclusion:The high percentage of mutations in the rpoB and katG genes highlights their importance, and should be further investigated in order to gain a more comprehensive of the geographical distribution of resistant strains, as well as of the mechanisms underlying them.

Keywords: Mycobacterium Tuberculosis, Rifampicin, Mutations, Isoniazid, line Probe Assay, Sudan.